Samsung Biologics Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Feb 11 to 27, 2027 · next Feb 11
- 1 fee due May 24, 2027The maintenance fee for Method of Treating Cancer Using Anti-C-Met Antibody and FGFR Inhibitor Combination Therapy (US 9,192,666) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 2 fees due Jun 15, 2027
- 1 fee due Jul 12, 2027The maintenance fee for Method of Treating Solid Cancers Using Anti-C-Met Antibody and Sorafenib Combination Therapy (US 9,233,155) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
- 1 fee due Sep 15, 2027The maintenance fee for Method of Screening Antibodies with High Antigen Selectivity (US 9,285,371) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 29 US 12,746,493 Filter Unit
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,546,544 | Antibody Specifically Binding to C-Met and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,563,696 | Antibody Specifically Binding to C-Met In force · High confidence | In force | High confidence | |
| US 8,987,425 | Pharmaceutical Composition for Preventing or Treating Cancer In force · High confidence | In force | High confidence | |
| US 8,859,507 | Protein Complex for Intracellular Delivery and Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,501,917 | Anti C-Met Antibody and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,101,610 | Anti C-Met Humanized Antibody and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,394,367 | Antibody Specifically Binding to Epitope in Sema Domain of C-Met In force · High confidence | In force | High confidence | |
| US 9,777,072 | Protein Complex and Method of Preparing Same In force · High confidence | In force | High confidence | |
| US 9,213,031 | Use of CBL as Biomarker for Identifying Subject Suitable for Treatment with Anti-C-Met Antibody In force · High confidence | In force | High confidence | |
| US 9,213,032 | Use of LRIG1 as a Biomarker for Identifying a Subject for Application of Anti-C-Met Antibodies In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded